Blue Cross Blue Shield Antitrust Settlement Final Approval

This landmark multidistrict litigation, initiated in 2012, alleged that the Blue Cross Blue Shield Association and its member plans conspired to allocate geographic markets and restrict competition among themselves, inflating insurance premiums for millions of subscribers in violation of the Sherman Act. After years of litigation and a prior settlement that was partially overturned on appeal, the parties reached a new $2.83 billion settlement in late 2024. On February 26, 2025, U.S. District Judge R. David Proctor in the Northern District of Alabama granted final approval to the settlement, the largest healthcare antitrust class action settlement in U.S. history. The settlement also requires the defendants to eliminate certain anti-competitive rules, such as the nationwide best rating rule, fundamentally altering the structure of the Blue Cross Blue Shield system to foster competition.

On February 26, 2025, the court granted final approval to a $2.83 billion settlement fund for affected subscribers and imposed an injunction that prohibits key anti-competitive conduct, including the rescission of the national best rating rule, thereby restructuring how Blue plans may compete.

Whether the Blue Cross Blue Shield Association and its member plans violated Section 1 of the Sherman Act by entering into a horizontal market allocation agreement that restrained intrabrand competition through exclusive service areas and other restrictive practices.

The settlement injected billions back into the hands of consumers and businesses and dismantled decades-old competitive barriers in the health insurance market. It is expected to increase competition among Blue Cross Blue Shield entities, potentially lowering premiums and improving coverage options. The case also sets a precedent for challenging structural market allocation schemes in the healthcare industry.